335 related articles for article (PubMed ID: 30152019)
1. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
5. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
6. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
8. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
Liu C; Li Z; Wang S; Fan Y; Zhang S; Yang X; Hou K; Tong J; Hu X; Shi X; Wang X; Liu Y; Che X; Qu X
J Cancer Res Clin Oncol; 2019 Jan; 145(1):65-76. PubMed ID: 30357521
[TBL] [Abstract][Full Text] [Related]
9. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
10. A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas.
Deng X; Chen K; Ren J; Zeng J; Zhang Q; Li T; Tang Q; Zhu J
Front Mol Biosci; 2022; 9():849723. PubMed ID: 35928223
[TBL] [Abstract][Full Text] [Related]
11. The role of CD28 in the prognosis of young lung adenocarcinoma patients.
Sun D; Tian L; Bian T; Zhao H; Tao J; Feng L; Liu Q; Hou H
BMC Cancer; 2020 Sep; 20(1):910. PubMed ID: 32967633
[TBL] [Abstract][Full Text] [Related]
12. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
[TBL] [Abstract][Full Text] [Related]
13. Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma.
Zhang C; Zhang Z; Sun N; Zhang Z; Zhang G; Wang F; Luo Y; Che Y; He J
Oncoimmunology; 2020 Sep; 9(1):1824641. PubMed ID: 33457102
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
15. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
16. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
17. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
Zhang C; Zhang Z; Zhang G; Zhang Z; Luo Y; Wang F; Wang S; Che Y; Zeng Q; Sun N; He J
Cancer Lett; 2020 Jun; 479():31-41. PubMed ID: 32201203
[TBL] [Abstract][Full Text] [Related]
19. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]